Tables index

From

A Comprehensive Prospective Study to Understand Chikungunya Infection in Delhi Region during 2010-2011

Singh Pradeep Kumar, Dar Lalit, Broor Shobha

American Journal of Microbiological Research. 2020, 8(4), 117-135 doi:10.12691/ajmr-8-4-2
  • Table 1. Primers used for RT-PCR amplification of E1
  • Table 2. Demographics of patients enrolled with suspected Chikungunya acute illness (≤15 days duration)
  • Table 3. Age and gender wise distribution of suspected Chikungunya patients with acute illness (≤15 days duration)
  • Table 4. Distribution by duration of illness of suspected Chikungunya patients enrolled with acute illness (<15 days duration)
  • Table 5. Demographics of patients enrolled with persisting polyarthralgia (Chronic illness; >15 days duration)
  • Table 6. Age and gender wise distribution of patients with persisting polyarthralgia (Chronic illness; >15 days duration)
  • Table 7. Distribution by duration of illness of patients enrolled with persisting polyarthralgia (Chronic phase; >15 days duration)
  • Table 8. Age group and gender wise distribution of suspected and MAC-ELISA positive Chikungunya patients with acute illness (<15 days duration)
  • Table 9. CHIKV IgM positivity by duration of illness in Chikungunya patients with acute illness (<15 days duration)
  • Table 10. Comparison of clinical features among CHIKV IgM positive and CHIKV IgM negative patients of Chikungunya in acute phase (<15 days duration)
  • Table 11. Monthly distribution of suspected and confirmed by ELISA Chikungunya cases from suspected Chikungunya patients during the study period
  • Table 12. Age group and gender wise distribution of patients with chronic polyarthralgia and MAC-ELISA positive Chikungunya patients. (Chronic illness; >15 days duration)
  • Table13. anti-CHIKV IgM positivity by duration of illness in Chikungunya patients with chronic illness (>15 days duration)
  • Table 14. RT-PCR and IgM positivity among acute phase (<15 days duration) samples by duration of illness
  • Table 15. RT-PCR and IgM positivity among chronic phase (>15 days duration) samples by duration of illness
  • Table 16. RT-PCR and CHIKV IgM ELISA positivity among follow up samples
  • Table 17. CHIKV viral load by duration of illness